Koss Olinger Consulting LLC Buys Shares of 62,881 GSK plc (NYSE:GSK)

Koss Olinger Consulting LLC purchased a new position in GSK plc (NYSE:GSK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 62,881 shares of the pharmaceutical company’s stock, valued at approximately $2,421,000.

A number of other large investors also recently modified their holdings of GSK. Cohen Investment Advisors LLC purchased a new position in GSK during the second quarter worth about $349,000. Blair William & Co. IL raised its stake in GSK by 14.9% in the first quarter. Blair William & Co. IL now owns 23,493 shares of the pharmaceutical company’s stock valued at $1,007,000 after purchasing an additional 3,044 shares in the last quarter. JPL Wealth Management LLC bought a new stake in GSK during the fourth quarter valued at approximately $1,129,000. SG Americas Securities LLC grew its stake in GSK by 448.7% in the 1st quarter. SG Americas Securities LLC now owns 17,690 shares of the pharmaceutical company’s stock worth $758,000 after buying an additional 14,466 shares in the last quarter. Finally, CreativeOne Wealth LLC bought a new position in shares of GSK in the 1st quarter worth $235,000. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on GSK shares. The Goldman Sachs Group started coverage on shares of GSK in a research report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price for the company. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Citigroup upgraded shares of GSK to a “strong-buy” rating in a research report on Monday, June 24th. Jefferies Financial Group boosted their price objective on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, Berenberg Bank raised shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Four analysts have rated the stock with a hold rating, two have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $50.00.

GSK Price Performance

Shares of GSK stock opened at $43.67 on Friday. The business has a 50 day moving average of $40.54 and a 200 day moving average of $41.64. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The company has a market cap of $90.51 billion, a PE ratio of 15.82, a P/E/G ratio of 1.42 and a beta of 0.66. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be issued a $0.3843 dividend. The ex-dividend date is Friday, August 16th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a yield of 3.52%. GSK’s dividend payout ratio is 54.71%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.